PRINCETON, N.J. & WILMINGTON, Del.--(BUSINESS WIRE)-- Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug ...

Bristol-Myers Squibb and AstraZeneca announced positive results from a Phase 3 study of dapagliflozin as add-on therapy to metformin for the treatment of type 2 diabetes. This 24-week, randomized, ...

Extension of study evaluated safety and efficacy of dapagliflozin plus metformin versus placebo plus metformin at 102 weeks Update on overall safety profile provided In addition to sustained ...

The DAPPER study was conducted with the National Cardiovascular Center as the principal investigator, with 294 patients participating from 18 facilities in Japan. In this study, we investigated ...

The US Food and Drug Administration (FDA) has approved a once-daily oral fixed-dose medication, called Qtern, combining 5 mg of the DPP-4 inhibitor saxagliptin (Onglyza, AstraZeneca) and 10 mg of the ...

African American Woman Tests Blood Sugar. Blood sugar is slightly high. A large multinational study examined the potential impact of dapagliflozin on kidney disease in people with type 2 diabetes.

The SGLT2 inhibitor dapagliflozin increases insulin clearance in type 2 diabetes when used as an add-on to metformin or combined with the DPP-IV inhibitor saxagliptin plus metformin, study data show.

WILMINGTON, Del.--(BUSINESS WIRE)--Combination of zibotentan with dapagliflozin showed statistically significant and clinically meaningful reductions in urinary albumin-to-creatinine ratio (UACR), ...

Authors report theirs is the first real-world study comparing the 2 SGLT2 inhibitors. A recently published study that compared patients with type 2 diabetes (T2D) taking the highest dose of ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BOSTON -- The ...